TLDR
- NanoVibronix surges on new ENvue patent, boosting medtech edge.
- ENvue patent sparks 65% NAOV rally, expanding IP-driven strategy.
- NAOV stock soars as ENvue wins U.S. patent for navigation system.
- New ENvue patent fuels NAOV momentum in medical device market.
- NanoVibronix strengthens IP moat with ENvue navigation patent
NanoVibronix, Inc. (NASDAQ: NAOV) surged nearly 65% during Monday trading, closing at $10.70 after extreme intra-day volatility.
NanoVibronix, Inc. (NASDAQ: NAOV)
The stock peaked above $17.50 before pulling back, suggesting strong initial momentum and rapid profit booking. After-hours trading saw a 5.42% dip to $10.12, signaling a partial retracement following the steep rally.
The move followed the announcement of a new patent issued by the United States Patent and Trademark Office on September 9, 2025. The patent, titled “Insertion Device Positioning Guidance System and Method,” belongs to ENvue Medical Holdings LLC, a wholly-owned subsidiary of NanoVibronix. The development marks a major addition to the Company’s growing intellectual property portfolio in the navigation systems market.
The newly granted patent protects electromagnetic positioning technology that enhances precision in feeding tube insertions. The method enables real-time visualization of device placement, reducing misplacement risks and procedural complications. This technology strengthens the Company’s competitive advantage in minimally invasive navigation systems.
ENvue Platform Bolsters NanoVibronix’s IP Portfolio
ENvue Medical developed the electromagnetic-based ENvue™ Navigation Platform, which already holds FDA 510(k) clearance for adult use. The system assists clinicians with accurately placing feeding tubes directly at the bedside and is designed to improve safety and efficiency during gastrointestinal access procedures.
The new patent reinforces NanoVibronix’s strategy to build long-term value through innovation and IP-driven barriers to market entry. It adds to an expanding list of granted patents in both U.S. and international markets. The Company views its intellectual property as a key growth driver and competitive differentiator.
ENvue’s system aims to reduce procedure time and improve outcomes for patients needing enteral nutrition support. With further expansion planned into pediatric and vascular access applications, the platform positions NanoVibronix for wider adoption. The Company expects this technology to enhance its presence in both hospital and alternate care settings.
Background and Strategic Focus
Headquartered in Tyler, Texas, NanoVibronix also operates research facilities in Israel and offices in Illinois. The Company focuses on acoustic-based and electromagnetic medical technologies targeting pain relief, infection reduction, and device placement. Current offerings include PainShield® and UroShield®, both designed for use in clinical and home care settings.
NanoVibronix continues to invest in product innovation and global IP protection as part of its long-term business strategy. The Company emphasizes safety, usability, and clinical value across its product lines. It remains committed to advancing non-invasive therapeutic technologies across healthcare environments worldwide.
With a combination of regulatory clearance, growing patent coverage, and product expansion plans, NanoVibronix strengthens its foothold in the medical device space. The market response reflects optimism around its technological edge and future growth potential.
